Published by Coherent Market Insights
Posted on September 14, 2021
3 min readLast updated: February 10, 2026
Add as preferred source on Google
Pemetrexed, sold under brand name Alimta by Eli Lilly and Company is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer. In February 2004, Eli Lilly and Company received U.S. Food and Drug Administration approval for pemetrexed for treatment of malignant pleural mesothelioma, and in 2008, company received another approval from FDA for treatment of advanced and metastatic non-small cell lung cancer.
Alimta is a folate analog metabolic inhibitor and in combinations with certain drugs it is indicated for various diseases:
In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC)
As a single agent for the maintenance and treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC), whose disease has not progressed after four cycles of platinum-based first-line chemotherapy
As a single agent for the treatment of patients with recurrent metastatic nonsquamous non-small cell lung cancer (NSCLC) after prior chemotherapy
In combination with cisplatin, for the initial treatment of patients with malignant pleural mesothelioma (MPM) whose disease is unresectable or who are otherwise not candidates for curative surgery
Get Sample Copy Of Research Report
Approval and Launch of Affordable Generic of Pemetrexed in Market is Expected to Increase its Adoption
Alimta is a patented drug of Eli Lilly and Company and is protected by a vitamin regimen patent (2021), and pediatric exclusivity (2022) in the U.S., vitamin regimen patent (2021) in major European countries, and patents covering use to treat cancer concomitantly with vitamins (2021) in the Japan.
However, Eli Lilly and Company’s compound patent for Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015.
Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period.
For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.
Furthermore, Eli Lilly and Company is dedicated in frequent research and development in order to expand the indication of Alimta and to generate high revenue benefits.
Market Dynamics
Launch of generic version of pemetrexed in key region is expected to increase affordability of pemetrexed, which in turn is expected to support global pemetrexed market growth over the forecast period.
For instance, in July 2018, STADAPHARM GmbH, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe.
High prevalence of non-small cell lung cancer and pleural mesothelioma is expected to rise the demand for Pemetrexed for its treatment and support global pemetrexed market growth over the forecast period.
Major Players Are: Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc.
Purchase This Premium Report Here With Discounted Price (Flat US $2000 Off) – https://www.coherentmarketinsights.com/promo/buynow/2458
Contact Us:
Name: Mr. Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Positive Trend of COVID-19 on Pemetrexed Market and Exhibit with 1.3% CAGR through 2027 appeared first on Gatorledger.
Pemetrexed, sold under the brand name Alimta, is a chemotherapy drug indicated for the treatment of pleural mesothelioma and non-small cell lung cancer.
The article suggests a positive trend in the Pemetrexed market due to COVID-19, with an expected CAGR of 1.3% through 2027.
The launch of affordable generic versions of Pemetrexed is expected to increase its adoption and affordability, supporting market growth.
Major players include Eli Lilly and Company, Stada Arzneimittel AG, and Eagle Pharmaceuticals, Inc.
The high prevalence of non-small cell lung cancer and pleural mesothelioma is expected to drive the demand for Pemetrexed for its treatment.
Explore more articles in the Research Reports category
